– Petosemtamab 1500 mg monotherapy phase 2 interim data continues to demonstrate clinically meaningful activity in 2L+ HNSCC – Conference…
November 09, 2024 13:00 ET | Source: Replimune Group Inc Oral presentation highlighting IGNYTE primary analysis data shows anti-tumor activity…